Vimarsana
Biggest News Aggregation in the World

Page 30 - Dave Fredrickson News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Dave Fredrickson. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Dave Fredrickson Today - Breaking & Trending Today

Top UK Stocks to Watch: Beazley shares jump despite pandemic-induced loss - Vimarsana News

Top UK Stocks to Watch: Beazley shares jump despite pandemic-induced loss

Beazley expects to bounce back strongly this year, Syncona’s investment in Achilles could benefit as it considers an IPO, Silence Therapeutics raises funds to help capitalise on current momentum, and energy suppliers like SSE and Centrica rise as Ofgem raises its price cap.

Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Update on KESTREL Phase III trial for Imfinzi - Vimarsana News

Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Update on KESTREL Phase III trial for Imfinzi

  Update on KESTREL Phase III trial of Imfinzi with or without tremelimumab in the 1st-line treatment of recurrent or metastatic head and neck cancer   The KESTREL Phase III trial for AstraZeneca's Imfinzi (durvalumab) did not meet the primary endpoint of improving overall survival (OS) versus the EXTREME treatment regimen (chemotherapy plus cetuximab), a standard of care, in the 1st-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose tumours expressed high levels of PD-L1. Also, the combination of Imfinzi plus...

AstraZeneca's Imfinzi drug fails in head and neck cancer trial - Vimarsana News

AstraZeneca's Imfinzi drug fails in head and neck cancer trial

(Reuters) - AstraZeneca said on Friday its Imfinzi drug did not prolong survival in a trial testing it as an initial treatment of head and neck cancer...

Source: wtbx.com
TAGRISSO Extended Disease-Free Survival Regardless of Prior Adjuvant Chemotherapy in Early-Stage EGFR-Mutated Lung Cancer - Vimarsana News

TAGRISSO Extended Disease-Free Survival Regardless of Prior Adjuvant Chemotherapy in Early-Stage EGFR-Mutated Lung Cancer

  In the ADAURA Phase III trial, chemotherapy use was balanced across the two treatment arms, with 60% of patients receiving prior adjuvant chemotherapy. In line with uptake observed in prior studies and clinical practice, younger patients (

Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Calquence approved in Japan for CLL - Vimarsana News

Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Calquence approved in Japan for CLL

  relapsed or refractory chronic lymphocytic leukaemia   progression after 12 months vs. 68% for comparators   AstraZeneca's Calquence (acalabrutinib), a next-generation, selective Bruton's tyrosine kinase (BTK) inhibitor, has been approved in Japan for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) (including small lymphocytic lymphoma [SLL]).   The approval by the Japanese Ministry of Health, Labour and Welfare was based on positive results from the ASCEND Phase III trial and a Phase I tr...